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Abstract
Background: MammaTyper is a novel CE-marked in vitro diagnostic RT-qPCR assay which assigns routinely
processed breast cancer specimens into the molecular subtypes Luminal A-like, Luminal B-like (HER2 positive or
negative), HER2 positive (non-luminal) and Triple negative (ductal) according to the mRNA expression of ERBB2, ESR1,
PGR and MKI67 and the St Gallen consensus surrogate clinical definition. Until now and regarding formalin-fixed,
paraffin-embedded material (FFPE), this has been a task mostly accomplished by immunohistochemistry (IHC).
However the discrepancy rates of IHC for the four breast cancer biomarkers are frequently under debate, especially
for Ki-67 which carries the highest degree of inter- and even intra-observer variability. Herein we describe a series of
studies in FFPE specimens which aim to fully validate the analytical performance of the MammaTyper assay,
including the site to site reproducibility of the individual marker measurements.
Methods: Tumor RNA was extracted with the novel RNXtract RNA extraction kit. Synthetic RNA was used to assess the
sensitivity of the RNXtract kit. DNA and RNA specific qPCR assays were used so as to determine analyte specificity of
RNXtract. For the assessment of limit of blank, limit of detection, analytical measurement range and PCR efficiency of
the MammaTyper kit serial dilutions of samples were used. Analytical precision studies of MammaTyper were built
around two different real time PCR platforms and involved breast tumor samples belonging to different subtypes
analyzed across multiple sites and under various stipulated conditions. The MammaTyper assay robustness was tested
against RNA input variations, alternative extraction methods and tumor cell content.
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Results: Individual assays were linear up to at least 32.33 and 33.56 Cqs (quantification cycles) for the two qPCR
platforms tested. PCR efficiency ranged from 99 to 109 %. In qPCR platform 1, estimates for assay specific inter-site
standard deviations (SD) were between 0.14 and 0.20 Cqs accompanied by >94 % concordant single marker
assignments for all four markers. In platform 2, the inter-site SD estimates were between 0.40 and 0.66 Cqs while the
concordance for single marker assignments was >94 % for all four markers. The agreement reached between the two
qPCR systems located in one site was 100 % for ERBB2, 96.9 % for ESR1, 97.2 % for PGR and 98.6 % for MKI67. RT-qPCR
for individual markers was stable up to a 64-fold dilution for a typical clinical sample. There was no change in assay
performance detected at the level of individual markers or subtypes after using different RNA isolation methods. The
presence of up to 80 % of surrounding non-tumor tissue including in situ carcinoma did not affect the assay output.
Sixteen out of 20 RNXtract eluates yielded more than 50 ng/μl of RNA (average RNA output: 233 ng/μl), whereas DNA
contamination per sample was restricted to less than 15 ng/μl. Median recovery rate of RNA extraction was 91.0 %.
Conclusions: In this study the performance characteristics of MammaTyper were successfully validated. The various
sources of analytical perturbations resulted in negligible variations in individual marker assessments. Therefore,
MammaTyper may serve as a technical improvement to current standards for decentralized FFPE-based routine
assessment of the commonly used breast cancer biomarkers and for molecular subtyping of breast cancer specimens.
Keywords: MammaTyper, Analytical validation, Reproducibility, FFPE, RT-qPCR, Breast cancer, ERBB2, ESR1, PGR, MKI67
Background
Despite substantial progress in diagnosis and treatment
of breast cancer during the past decades, approximately
15 % of all newly diagnosed breast cancer patients will still
die of the disease within the first 5 years [1]. Classic histo-
pathology, immunohistochemistry (IHC), pTNM staging
and clinical characteristics have traditionally been used to
estimate a patient’s risk of relapse and long-term outcome
and provide indications on (neo)adjuvant treatment. In
recent years molecular profiling of breast cancer has
prompted actions towards more precise stratification of
individual patients and more informed treatment deci-
sions [2]. The so called “intrinsic” subtypes (Luminal A,
Luminal B, HER2-positive and Basal-like), although not
unrelated to long-established breast cancer phenotypes,
likely represent separate diseases with distinct underlying
biology and clinical characteristics. Accumulating evi-
dence suggests that these molecular entities hold signifi-
cant information with regard to prognosis, time-point and
location of distant metastases and benefit of therapies.
The exact determination of these molecular subtypes may
enhance the prognostic power of traditional clinicopatho-
logical parameters [3].
The prototypic molecular subtypes were identified by
microarray technology investigating mRNA expression
patterns of 1,753 genes in 84 patient samples [4], 8.000
genes in 122 patient samples [5] or 306 genes in 416 pa-
tient samples [6]. Attempts to enable integration of these
findings into the routine pathology diagnostic workup
led to the development of a 50 gene signature for the de-
termination of the intrinsic subtypes [7] and the transfer
of this signature onto a diagnostic platform [8]. How-
ever, as this approach for subtyping requires specialized
instrumentation, it is mainly reserved for diagnostically
challenging cases, whereas the current widely adopted
standard for breast cancer subtyping is based on a surro-
gate protein-based classification system for clinical use
[9]. This approach has been embraced by the St Gallen
International Expert Consensus on the Primary Therapy
of Early Breast Cancer since 2011 as a novel paradigm
for the classification of patients for therapeutic purposes
[2]. These surrogate definitions require a small panel of
antibodies against estrogen receptor (ER), progesterone
receptor (PR), human epidermal growth factor receptor
2 (HER2) and proliferation antigen Ki-67. Thereby, a man-
ageable, clinically meaningful and continuously updated
approximation of the molecular subtypes by immunohisto-
chemistry (IHC) can be achieved. Classification of tumor
samples according to these clinico pathological surrogates
is carried out by first assessing the binary expression status
(positive versus negative) of the aforementioned markers.
Individual assessments are then used for feeding the
classification rules of Table 1, an approach which is
conceptually as well as procedurally different than the
50 markers, centroid-based prediction methodology of
the Prosigna assay.
In recent years, growing concerns over the reproduci-
bility of routine assessment of breast cancer biomarkers
by IHC with reported discordance rates of up to 20 %
for ER and HER2, have motivated the development of
detailed guidelines to improve the accuracy of testing
[10–13]. While the average discrepancy rate in defined
clinical settings for ER, PR and HER2 is frequently under
debate, it is beyond any doubt that among all four breast
cancer biomarkers, Ki-67 carries the highest degree of
inter- and even intra-observer variability which makes
scoring particularly hard to reproduce even between ex-
perienced pathologists [14, 15]. Reported intra-observer
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Kappa values of as low as 0.00–0.35 illustrate an alarm-
ing variability of the current Ki-67 scoring methods [15].
Although no study has yet addressed the relation be-
tween single marker discrepancies and the rate of mis-
classification of breast tumors into molecular subtypes,
it is probable that significant uncertainty exists particu-
larly in the critical distinction between Luminal A- and
B-like tumors, due to multiplying error probabilities of
individual markers. Recent efforts to improve the con-
cordance of Ki-67 scoring have demonstrated that agree-
ment between pathologists using a specific scoring
method and following training can lead to a significant
improvement of scoring concordance. However, these
standardized methods are not yet adopted widely and
also lack clinical validation [16, 17].
The limitations of current methods for routine mo-
lecular subtyping of breast cancer highlight the need for
more reliable, well standardized and less subjective as-
says. However, it is also important that these assays can
be performed in a decentralized environment, where
close collaboration between pathologists and clinicians
and faster turnaround are beneficial for both patients
and medical practitioners. Reverse-transcription quanti-
tative real time PCR (RT-qPCR) has been previously
considered a reasonable alternative to IHC due to sev-
eral competing advantages; it is quantitative, it is not af-
fected by inter-observer variability, interpretation of
results is straightforward and the technique can be per-
formed locally in a standardized and automated manner
largely irrespective of sample size [18–20].
The MammaTyper gene expression assay is a CE-
marked in vitro molecular diagnostic test which mea-
sures the mRNA expression levels of the four genes
ERBB2, ESR1, PGR and MKI67 in surgical breast cancer
samples and pre-operative biopsies to assign a tumor to
a molecular subtype (Luminal A-like, Luminal B-like
(HER2 positive or negative), HER2 positive (non-luminal)
and Triple negative (ductal)). The quantitative format of
biomarker detection has the potential to be used for the
prediction of response to systemic treatments [21, 22].
The assay is based on RT-qPCR of total RNA extracted
from formalin-fixed paraffin-embedded (FFPE) material
and can be run locally on widely accessible qPCR instru-
ments. The workflow includes a novel standardized nu-
cleic acid extraction kit (RNXtract RNA Extraction Kit,
BioNTech Diagnostics GmbH, Mainz) for the isolation of
high-quality tumor RNA.
Results from a recent clinical validation study in 769
patients from the FinHER clinical trial population
showed that subtyping by MammaTyper results in a bet-
ter prediction of patient outcome than when subtyping
was based on local IHC data (Wirtz et al. submitted).
Accordingly, the test result is prognostic for the patients’
risk for distant metastases and overall survival and sup-
ports the prediction of benefit from the addition of tax-
ane to adjuvant chemo-endocrine therapy. The clinical
performance of the MammaTyper assay is currently in-
terrogated in multiple additional prospective/retrospect-
ive settings so as to meet the high standards for clinical
validity required for diagnostic applications tested on ar-
chived specimens [23].
Apart from clinical validation, recent guidelines high-
light the importance of formal testing procedures for es-
timating a diagnostic assay’s analytical performance
before it is accepted for clinical use [24]. Herein we
undertook a rigorous analytical validation of the
RNXtract kit and the MammaTyper assays accounting
for multiple factors of the analytical process from tumor
RNA isolation and the assessment of each single bio-
marker to the algorithmic determination of breast can-
cer molecular subtypes. The design of the studies has
been optimized to make best use of established guide-
lines such as the evaluation of precision of quantitative
measurement methods (EP5-A3) issued by the Clinical
and Laboratory Standards Institute (CLSI) and the Mini-
mum Information for Publication of Quantitative Real-
Time PCR Experiments (MIQE) guidelines [25, 26].
Moreover, two of the testing sites were independent mo-
lecular pathology laboratories.
Methods
Sample selection and assay description
RNA for each sample was extracted from a single non-
macrodissected 10 μm-thick FFPE section with the
Table 1 Subtyping algorithm of breast cancer specimens
according to St Gallen consensus 2013
ERBB2 ESR1 PGR MKI67 St Gallen 2013 equivalent
pos pos pos pos Luminal B-like (HER2 positive)
pos pos pos neg Luminal B-like (HER2 positive)
pos pos neg pos Luminal B-like (HER2 positive)
pos pos neg neg Luminal B-like (HER2 positive)
pos neg pos pos Not defined
pos neg pos neg Not defined
pos neg neg pos HER2 positive (non-luminal)
pos neg neg neg HER2 positive (non-luminal)
neg pos pos pos Luminal B-like (HER2 negative)
neg pos pos neg Luminal A-like
neg pos neg pos Luminal B-like (HER2 negative)
neg pos neg neg Luminal B-like (HER2 negative)
neg neg pos pos Not defined
neg neg pos neg Not defined
neg neg neg pos Triple negative (ductal)
neg neg neg neg Triple negative (ductal)
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RNXtract kit (BioNTech Diagnostics GmbH). Pathologic
review of a representative H&E-stained slide (biopsy or
resection specimen) ensured the presence of sufficient
tumor tissue with at least 20 % tumor cell content. A de-
scription of basic clinical and pathological characteristics
of the samples used herein may be found in Additional
file 1A. The RNXtract RNA extraction kit employs
germanium-coated paramagnetic particle technology in
order to segregate RNA from FFPE material with prefer-
ence over DNA. The procedure begins with paraffin
melting and buffer-controlled tissue lysis, followed by
proteinase K digestion. Thereafter, lysates are incubated
with magnetic beads under optimized buffer conditions
which favour binding of RNA molecules. Contaminants
are then progressively removed through sequential wash-
ing steps, during which paramagnetic particles with at-
tached nucleic acids are kept magnetized, while the
supernatant is removed. At the final step, RNA is released
from the magnetic beads into 100 μl of elution buffer.
With MammaTyper reverse transcription of RNA and
amplification of cDNA take place successively in one re-
action mix, which contains all the necessary enzymes
and hydrolysis primer/probe sets specific for the target
sequences of interest. For the various analytical perform-
ance experiments forty cycles of nucleic acid amplifica-
tion were applied and the quantification cycle (Cq)
values of the target and reference genes were estimated
as the median of triplicate measurements per RT-qPCR
run. Median Cq values of the triplicate measurements
(from now on simply Cq) for each of the 4 different
genes of interest (GOI) were normalized against the
mean expression of the two reference genes (REF) and
presented as ΔΔCq values relative to the positive control
[27]. The final values were generated by subtracting
ΔΔCq from the total number of cycles so that test re-
sults are positively correlated, a format that facilitates in-
terpretation for clinical decision making:
40−ΔΔCq GOIð ÞS ¼ 40−

Cq GOI½ sample –meanCq REF½ sample
 
– Cq GOI½ pc– meanCq REF½ pc
 
The test output comprises the normalized raw data of
individual biomarkers and the molecular subtype of
breast cancer, according to the algorithm depicted in
Table 1. Each sample is assigned into Luminal A-like,
Luminal B-like (HER2 positive or HER2 negative), HER2
positive (non-luminal) and Triple negative subtypes, after
dichotomizing continuous RNA output values per
marker into “Positive” and “Negative” results according
to clinically established and qPCR device-specific cut-
offs (Additional file 1B). Assay controls are included to
ensure that specimens and RT-qPCR runs satisfy pre-
specified quality thresholds. These controls comprise
two internal reference genes (REF) for assessment of
sample validity and normalization (B2M, CALM2) as
well as one positive (PC) and one negative (no-template
control; NTC) external control for qualification of the
RT-qPCR process (Additional file 1C). The aforemen-
tioned cut-off values for ERBB2, ESR1 and PGR were
established in a cohort of 135 breast cancer patients,
based on the highest concordance achieved between
relative RNA amplification and corresponding protein
expression by high-quality IHC as the gold standard.
Due to the uncertainty of Ki-67 IHC data the MKI67
cut-off of the assay under development (Stratifyer Mo-
lecular Pathology GmbH) was set at the 3rd quartile of
the normally distributed MKI67 expression data from 90
FFPE breast cancer tumor samples. These had been pre-
viously analysed in the context of a clinical outcome pre-
diction study [28]. The cut-off was then transferred from
the assay under development to the MammaTyper IVD
by parallel measurement of 135 clinical breast cancer
samples and matching of cut-offs on this sample set.
Analytical specificity and analytical sensitivity
It is common that DNase I digestion is included as an
extra step during the process of RNA quantification in
order to eliminate genomic DNA (gDNA) contamination
and increase specificity of the extraction-amplification
sequence. In order to test the analytical specificity of the
RNXtract method, eluates were prepared from 20 breast
cancer samples and equally divided in two aliquots for
the estimation of the amount of RNA or DNA with the
standard curve method. For this purpose, in aliquot No
1, B2M RNA transcripts were measured by RT-qPCR
using serial dilutions of the MCF7 cell-line total RNA
(BioCat) as standard curve, while in aliquot No 2 qPCR
was applied using a commercial gDNA quantification
assay for qPCR (primer design) and serial dilutions of a
commercial gDNA as standard curve. All experiments
were performed on a Roche LightCycler 480 II qPCR in-
strument in triplicates. For assessing the effect of poten-
tial contamination by gDNA on the MammaTyper
result, RNA eluates from three different samples were
compared under varying conditions; according to stand-
ard methodology (non-digested samples), digested with
DNase I (Ambion) and treated like DNase I digested
samples, where DNase I was exchanged for water. Sam-
ples were processed in one run with positive and nega-
tive controls.
For assessing the sensitivity of extraction, 3 FFPE sam-
ples (1 × 10 μm) were spiked with commercial 4 μl
unique internal control RNA (Int-RNA) (primer design)
at the initial extraction step so as to determine the re-
covery rate. The obtained Cq values were compared
against a standard curve of Int-RNA serially diluted in
RNXtract elution buffer. Since the original concentration
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of the Int-RNA was not known, extraction efficiency was
estimated relative to that of the control sample (repre-
senting 100 % input). In addition, the extraction effi-
ciency was validated with respect to variations in the
range of input material. Two resection specimens and 6
standard core tumor biopsies (10 μm × 1.5 mm ×
20 mm) were serially cut and 10 samples were prepared
that differed by specimen type (resection versus biopsy),
thickness of paraffin curls (5 μm versus 10 μm) and
number of input curls (1, 2 or 3). The RNA concentra-
tion of the eluates was quantified with calibration to a
standard curve as described above for specificity.
The analytical sensitivity of the RT-qPCR was vali-
dated under conditions of reduced RNA template and
with respect to the test detection capacity according to
the standard methods provided in the EP17-A guideline
issued by the Clinical and Laboratory Standards Institute
(CLSI) [29]. Serially diluted samples from 3 RNA eluates
corresponding to different subtypes and RNA eluates
from six tumor biopsies were analyzed and the accept-
able range of B2M and CALM2 REF genes was used as a
quality control of sample validity according to the in-
structions for use. For further characterizing the analyt-
ical performance of MammaTyper the following formal
validation metrics were used. The LoB (limit of blank)
i.e., the highest measurement that is likely to be
observed for a blank sample, was determined separately
for each assay mix and for each qPCR system on 20 rep-
licates of NTC samples containing water (120 reactions
in total). Assuming a Gaussian distribution of the Cq
values, the LoB, was set at a mean Cq value of 40, ob-
served 95 % of times for each assay mix. The LoD (limit
of detection), defined as the smallest analyte concentra-
tion likely to be consistently distinguished from the LoB
and at which detection is feasible with a certain degree
of certainty was herein perceived as the amount of total
sample RNA (positive for all targets) at which the Cq
value was below the LoB with a probability of 95 %. The
LoQ (limit of quantification) was here defined as the
amount of target RNA for each marker producing a Cq
value which was (a) lower or equal to the Cq determined
for the LoD, and (b) displayed a distance to the regression
curve of the dilution series lower than 0.7 Cqs for each di-
lution of the clinical sample or the IVT-RNA (in-vitro
transcribed RNA). The distance value reflects previously
reported PCR replicate variation range of 0.5 to 1.0 Cq
[30]. The analytical measurement range for MammaTyper
assay was determined as the Cq range over which the
MammaTyper shows a linear signal (distance from regres-
sion curve ≤0.7 Cq) beginning at the LoD as the lowest in-
put value. For the LightCycler the analytical measurement
range is limited by the fix baseline settings (3–15).
A master sample prepared by pooling three eluates from
a single patient block (3 FFPE sections per extraction) was
measured with spectrophotometry (NanoDrop; Thermo
Scientific) and serially diluted in carrier RNA (10 ng/μl).
Dilution curves were analyzed with all three assay mixes
on both amplification systems. The same procedure was
carried out for MammaTyper IVT-RNA. The numbers of
molecules corresponding to the highest concentration of
the IVT-RNA were calculated online with a web-based
molecular weight calculator (http://www.currentprotocols.
com/WileyCDA/CurPro3Tool/toolId-8.html). The num-
ber of molecules in the master sample was extrapolated
from the respective linear function of the regression
curves of the IVT-RNA dilution series for each marker
and reference gene. Concentrations corresponding to Cq
values outside the analytical measurement range (as de-
fined by IFU-based instrument settings) were excluded
from the analysis.
Robustness
In the context of the robustness study the extraction
and RT-qPCR workflows were varied at various steps as
described in detail in Additional file 1D. RNA was ex-
tracted from one FFPE clinical sample and was quanti-
fied using the standard curve method. The stability of
RT-qPCR against pre-specified fluctuations of protocol
parameters was determined as the concordance between
subtypes generated under the varying conditions and of
subtypes assigned under the standard protocol to 4 clin-
ical breast cancer cases.
Pre-analytical processing concordance and tumor cell
content study
The following studies were designed in order to verify
that variability in pre-analytical processing steps, includ-
ing different methods for RNA extraction or the use of
macro-dissected versus full-face tissue sections, do not
substantially interfere with the stability of the RT-qPCR-
based MammaTyper breast cancer subtypes. For this
purpose RNA was extracted from 8 clinical FFPE sam-
ples with RNXtract and two other commercially avail-
able kits for extraction of RNA from FFPE tissues.
Eluates corresponding to the different extraction
methods were analyzed within the same RT-qPCR run.
Pathologically confirmed non-invasive tumor tissue in-
cluding normal breast lobules or ductal carcinoma in situ
(DCIS) is commonly part of full-face tumor sections used
for RNA extraction and is generally considered a source of
errors in gene-expression quantification by RT-qPCR. To
assess the possibility that contamination by non-invasive
tumor may affect the MammaTyper results, 9 clinical breast
cancer cases were selected in order to represent samples
with low tumor cell content (10–50 %) which were then
enriched up to 80 % upon careful macrodissection. The dif-
ferences between macrodissected and non-macrodissected
samples were recorded as disagreement affecting the status
Laible et al. BMC Cancer  (2016) 16:398 Page 5 of 14
of individual markers. By intention, all cases included DCIS
of variable extent (10-70 %) adjacent to tumor.
Analytical precision and reproducibility
For determining the reproducibility of MammaTyper,
two studies were performed on the two compatible
qPCR platforms, whereby the experiments were de-
signed according to hierarchy of investigated factors
(Study 1: Instrument/site – days – runs – replicates
within runs; Study 2: Instrument/site – extraction – run
(=days) – replicates within runs). The first study was
conducted on four LightCycler 480 instrument II
(Roche) devices utilizing pooled RNA extracted from
breast tumors. The outset of the second study, con-
ducted on three Versant kPCR Cyclers (Siemens) and
one LightCycler 480 instrument II (Roche), was FFPE
breast tissue sections and the aim was to investigate pre-
analytical factors and variations between qPCR instru-
ments from different suppliers. All operators partici-
pated in familiarization runs and were blinded to any
characteristic of the test samples which might create an-
ticipation for a specific output. Each sample was tested
in triplicates during each run along with the specified
positive and negative controls. One, 10 μm-thick tissue
section was input for RNA extraction irrespective of
tumor surface or tumor cellular content. The results of
the two studies have been combined and arranged by
qPCR system for presentation purposes.
Design of study 1
This comparative three-site study was conducted with
the MammaTyper by two operators on four LightCycler
480 II (Roche) devices to assess analytical performance
as presented in Table 2. The four instruments were in
place at the National Centre for Tumor Diseases in
Heidelberg, the BioNTech Diagnostics GmbH in Mainz
and the University Medical Center of the Johannes
Gutenberg University Mainz. Reference RNA (RNA
from several cancer cell lines) (Agilent) and RNA pools
from seven breast tumor samples were generated from
commercially available FFPE specimens for testing at
each site. The samples were selected to include the en-
tire range of the clinically anticipated expression levels
of the target genes, including values adjacent to the cut-
offs. Each sample was processed during six RT-qPCR cy-
cles, run on consecutive days at sites 1 and 2 but not at
site 3. The procedure was performed by the first operator
at site 1 and by the second operator at the two other sites
while at site 2 two different qPCR devices were used.
Design of study 2
This comparative three-site study used replicate breast
tumor tissue specimens from the same FFPE block for
testing with the MammaTyper (Table 2). A 16-member
panel of breast cancer samples (15 ductal carcinomas and
1 lobular carcinoma) obtained from commercial vendors
except for one clinical sample and comprising all different
tumor subtypes were analyzed. All tissue specimens were
sectioned at BioNTech Diagnostics GmbH. The first and
last section were analysed with MammaTyper at site 1
and showed nearly identical marker expression. After re-
arranging, sections were shipped to the other testing sites
(Stratifyer Molecular Pathology GmbH, Cologne and In-
stitute of Pathology, University of Erlangen). Each tissue
sample was processed during three, 4-day cycles, starting
with RNA extraction and aliquoting of eluates (day 1)
followed by three RT-qPCR runs on consecutive days (day
2–4). The procedure was performed by one operator per
site using a single instrument (Versant kPCR Cycler,
Siemens), a single lot of RNXtract and a single lot of the
MammaTyper Assay. At BioNTech Diagnostics six add-
itional cycles were performed by the same operator, two
with different MammaTyper lots, one with an alternative
RNXtract lot and three on a LightCycler 480 II (Roche)
qPCR device to account for related effects on precision.
Intra-run precision was estimated based on the vari-
ance of triplicate measurements. All calculations for the
precision studies were carried out based on CLSI guide-
line EP 05-A3 [25] using a random effects model II
ANOVA via PROC mixed in SAS Version 9.2.
Results
Analytical specificity and analytical sensitivity
Quantification of nucleic acids extracted from 20 FFPE
samples showed preferential extraction of RNA with a
Table 2 Overview of precision studies
Numbers
Study variable Study 1 Study 2
Samples 8 16
Intra-run replicates 3 3
Runs per device 6 9
Runs per day 2 1
Reagent lots per site 1 3/2a
Operators per site 1 1
Runs per site 6/12b 9/27c
Sites 3 3
Different qPCR instruments 4 4d
Operators 2 3
Total tests per device 48 144/288a
Total tests 192 720
aThree different lots of MammaTyper and two lots of RNXtract were used at
BioNTech Diagnostics to account for inter-lot precision
bIncluding two devices at BioNTech Diagnostics
cIncluding inter-lot precision and 1 Roche qPCR system at BioNTech Diagnostics
dIncluding 1 Roche qPCR system at BioNTech Diagnostics in order to address
variations caused by different instruments
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mean concentration of 232.8 ng/μl (95 % CI: 132.8-
332.8 ng/μl). By contrast, DNA levels remained consist-
ently below 15 ng/μl with a mean concentration of
5.5 ng/μl (95 % CI: 3.7-7.3 ng/μl) (Additional file 2A).
For the amplification assay, specificity was determined
by comparing the status of individual markers as well as
subtypes in 3 pairs of DNase I-treated and non-treated
samples. Under these varying conditions no difference
was observed between DNA-free samples and samples
potentially contaminated by DNA. Subtype and single
marker concordance was 100 % and no detectable amp-
lification was noticed for negative controls (Cq = 40)
(Additional file 2B).
The recovery rate of the 3 samples spiked with the
unique internal control was 73 %, 91 % and 99 %. Fur-
ther, RNA isolation was optimal for all variations of the
input material sensitivity experiment and remained con-
sistently above 10 ng/μl. Accordingly, RNA-rich eluates
were obtained even when samples were reduced to sin-
gle core needle biopsy or single 5 μm-thick full-face
slices. Amplification sensitivity was assessed on three
serially diluted samples (Triple negative, Luminal B-like
(HER2 negative) and HER2 positive (non-luminal)) and
on RNA extracted from six standard core needle biop-
sies. All marker results of the diluted samples were in
agreement with the results of the non-diluted specimen up
to the limit of sample validity as defined by the pre-
specified B2M and CALM2 Cq thresholds. Further, as
shown in Fig. 1, some of the individual marker assignments
remained stable up to a dilution factor of 256. All six bi-
opsy samples were valid according to assay specifications
resulting into efficient subtyping of the respective tumors.
Pre-analytical parameters study and robustness
Three 10 μm-thick sections were generated from each one
of eight FFPE tissue specimens and manually processed
with RNXtract and two additional commercially available
kits for extraction of RNA from FFPE tissue in order to es-
timate the effect of different isolation methods on Mam-
maTyper assay performance. Among the binary results
resulting from 96 measurements (valid specimens: 100 %)
there were three discrepant marker classifications involv-
ing PGR and MKI67 40-ΔΔCq values which were close to
the respective cut-offs (Fig. 2).
For estimating the effect of tumor cellularity on the ac-
curacy of MammaTyper output, pairs of dissected and
non-dissected samples were compared with respect to
relative gene expression and binary marker status. One
sample did not satisfy validity criteria and was excluded
from further calculations. As shown in Fig. 3, 40-ΔΔCq
differences across the tested pairs remained very low for
all markers, with an average difference of less than 0.47
Cq. Concordance was 100 % for ERBB2, ESR1, PGR
whereas for MKI67, one case containing 10 % tumor cells
was negative in the non-macrodissected sample. Macro-
dissection of FFPE tissue sections for gene-expression
analysis with the MammaTyper assay may be spared for
samples containing more than 10 % tumor cells.
Fig. 1 Performance of MammaTyper assay on serial dilutions of 3 breast cancer resection specimens. Filled symbols: Valid measurements. Unfilled
symbols: Invalid measurements
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The various potential failure modes tested in the ro-
bustness study for both the RNXtract and the Mamma-
Typer assays affecting binding and washing steps and
PCR parameters did not significantly alter the output.
For the extraction experiments this involved adequate
yields of RNA at concentrations which did not differ sig-
nificantly from standard conditions except when the
protein digestion step was omitted. For the MammaTy-
per the method failed upon omission of the reverse tran-
scription step. As expected, the failure was detected by
out-of-range median Cq values of the positive control.
For the other two failure modes there was perfect agree-
ment with respect to single markers.
LoB, LoD, LoQ, linearity
All blank measurements showed no amplification signal
up to 40 cycles. The LoQ was equal to the LoD for all
six assays on IVT-RNA as well as FFPE derived RNA
and both platforms Versant kPCR and LightCycler 480
instrument II. Data for the other metrics are summa-
rized in Table 3 for experiments run on the two different
qPCR systems for the FFPE RNA master sample and
Fig. 2 Effect of different commercial extraction kits on the performance of MammaTyper relative quantification of target genes, demonstrated at
8 samples
Fig. 3 Effect of tumor cell content on the accuracy of MammaTyper relative gene expression, demonstrated at 9 samples
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IVT-RNA (positive control) respectively. All assays were
linear at least up to 32.33 and 33.56 Cqs for the two
qPCR platforms tested. Amplification efficiencies ranged
from 99 to 109 %. The lower (Cq) border of the analyt-
ical measurement range (AMR) for IVT-RNA on the
LightCycler platform was limited by the fixed instrument
baseline settings of the test, whereas for the FFPE master-
sample the lower (Cq) border of the dilution curve
reflected the expression of the target genes which in turn
was restricted by the actual concentration of RNA in the
master-sample (96.7 ng/μl).
Precision
Precision was evaluated simultaneously for RNA extrac-
tion and for RT-qPCR with regard to various potential
sources of analytical variability such as qPCR instru-
ment, reagent lot/batch and site/operators. One hundred
percent of all specimens and measurements yielded valid
results according to assay specifications except in study
2 for one sample at site 1, for which extraction was
repeated using a reserve FFPE section. As expected,
no signals were detected for the negative controls up
to a Cq value of 40. The calculated test results of the
16 specimens adequately represent a wide range of
clinically encountered 40-ΔΔCq values of the individual
genes, both positive and negative calls for individual
markers.
Table 4 shows the estimated variance components
(expressed as standard deviations) generated by analyt-
ical and pre-analytical factors as well as the overall vari-
ance, for studies run on LightCycler 480 instrument II
platforms (Roche) (inter-run/site, intra-run data gener-
ated with 8 RNA-pools on 4 instruments, inter/within
section/extraction data generated on 16 samples with
3 cycles as described for the Versant instrument). The
assay specific inter-site standard deviation (SD) for the
entire set of the test samples was between 0.14 and 0.20
Cqs for Study No1. In this study there were only minor
differences in the variance reflecting different compo-
nents of precision. This indicates that the actual tripli-
cate measurement is the major source of analytical
imprecision and further noise is introduced only to a
minor degree when experiments are carried out on dif-
ferent days or different instruments. Moreover, variabil-
ity seemed to be homogenously distributed across the
measurements of the four target genes, indicating com-
parable assay performance.
The estimated parameter-specific and overall variance
for studies on Versant qPCR Cycler platforms (Siemens)
are depicted in Table 5. The estimates for assay specific
inter-site SD for the entire set of the test samples ranged
Table 3 Validation metrics of MammaTyper amplification for each different target sequence and sample type
Versant kPCR ERBB2 ESR1 PGR MKI67 B2M CALM2
FFPE Master Sample LoD [Cq] 34.36 35.54 32.33 35.66 35.80 34.78
LoD [molecules] 10 5 87 7 7 8
AMR [Cq] 21.05–34.36 19.13–35.54 21.13–32.33 23.97–35.66 16.78–35.80 23.90–34.78
Efficiency [%] 106 105 106 101 100 111
Linearity 0.999 0.999 0.995 0.999 0.999 0.998
IVT-RNA LoD [Cq] 35.31 35.60 36.72 36.41 36.22 33.69
LoD [molecules] 5 5 5 5 5 18
AMR [Cq] 12.36–35.31 12.45–35.60 12.64–36.72 11.63–36.41 12.41–36.22 11.67–33.69
Efficiency [%] 105 104 100 99 100 100
Linearity 0.999 0.999 1.000 0.999 1.000 1.000
LightCycler 480 II ERBB2 ESR1 PGR MKI67 B2M CALM2
FFPE Master Sample LoD [Cq] 33.56 36.47 33.56 35.47 35.6 35.62
LoD [molecules] 40 8 64 12 12 9
AMR [Cq] 22.32–33.56 21.69–36.47 21.20–33.56 24.61–35.47 17.60–35.60 25.26–35.62
Efficiency [%] 109 113 115 111 109 117
Linearity 1.000 1.000 0.996 0.999 0.999 0.997
IVT-RNA LoD [Cq] 34.64 35.21 35.44 34.91 34.97 36.51
LoD [molecules] 18 18 18 18 18 5
AMR [Cq] 17.34–34.64 18.52–35.21 17.56–35.44 19.27–34.91 17.9–34.97 18.87–36.51
Efficiency [%] 106 109 101 103 107 103
Linearity 1.000 0.999 1.000 0.999 0.999 1.000
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from 0.00 to 0.66 Cqs, whereby a value of 0 indicates
that the higher-order variance component is completely
covered by the lower order component. A small but no-
ticeable gradual increase in variability was observed
while progressing from lower to higher components of
precision. The data presented in Tables 4 and 5, col-
lectively reveal a characteristic difference in the noise
involving all testing parameters between experiments
conducted on different qPCR platforms. Interestingly,
biological variability, represented by inter-extraction
variance was lower or almost equal to the variability
between different aliquots of the same RNA eluate
(intra-extraction) for each one of the two instruments
(study 2), but it was overall higher for the Versant in-
strument. Thus, the same sources of analytical vari-
ation tested under similar conditions but on different
qPCR systems resulted in comparable but not identi-
cal variability of the measurements.
Concordance of individual marker and subtype
classifications
The gold standard for assessing concordance was set by
the most prevalent binary result across all measurements
between sites after applying the respective cut-offs
(positive versus negative). The average marker specific
between-site and between-instrument concordance was
over 97 % (Table 6) (over 94 % for subtypes) and it
reflected excellent reproducibility of relative gene ex-
pression for the individual targets as shown in Fig. 4, for
Study 1.
Discussion
Herein we have provided evidence that the quantification
of ERBB2, ESR1, PGR and MKI67 mRNA expression by
using optimally standardized RT-qPCR assays is feasible,
sensitive, specific and analytically precise.
Table 4 Analytical variation presented as standard deviations of the 40-ΔΔCq values (SD) with 95 % confidence intervals (CI) for
LightCycler 480 instrument II, Roche
LightCycler 480 II Study 1 Study 2





ExtractionDevice 1 (site 1) Device 2 (site 2) Device 3 (site 2) Device 4 (site 3)
ERBB2 SD 0.20 0.21 0.21 0.18 0.22 0.21 0.20 0.08 0.16
95 % CI 0.15–0.30 0.19–0.23 n.a. n.a. n.a. n.a. n.a. 0.05–0.19 0.14–0.19
ESR1 SD 0.18 0.27 0.26 0.27 0.21 0.31 0.30 0.52 0.55
95 % CI 0.13–0.29 0.24–0.30 n.a. n.a. n.a. n.a. n.a. 0.39–0.79 0.48–0.64
PGR SD 0.14 0.15 0.14 0.12 0.19 0.16 0.22 0.07 0.17
95 % CI 0.11–0.22 0.14–0.17 n.a. n.a. n.a. n.a. n.a. 0.04–0.26 0.15–0.20
MKI67 SD 0.20 0.18 0.18 0.14 0.15 0.23 0.20 0.05 0.17
95 % CI 0.16–0.30 0.16–0.20 n.a. n.a. n.a. n.a. n.a. 0.03–0.68 0.15–0.20
All data using models without day (inter-day variance is completely explained (covered) by inter-run variance). The calculations of inter- and within-section SDs
are derived from a single instrument (study 2), due to the use of pooled samples in study 1
Table 5 Analytical variation presented as standard deviations of the 40-ΔΔCq values (SD) with 95 % confidence intervals (CI) for























ERBB2 SD 0.48 0.21 0.41 0.35 0.31 0.15 0.39 0.00b 0.49 0.29 0.16
95 % CI 0.38–0.67 0.16–0.31 0.38–0.44 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a.
ESR1 SD 0.66 0.22 0.42 0.35 0.27 0.00b 0.29 0.18 0.61 0.26 0.09
95 % CI 0.53–0.90 0.16–0.33 0.39–0.46 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a.
PGR SD 0.00a 0.14 0.28 0.07 0.25 0.10 0.25 0.23 0.33 0.25 0.14
95 % CI n.a. 0.11–0.20 0.26–0.30 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a.
MKI67 SD 0.40 0.14 0.31 0.19 0.27 0.10 0.26 0.08 0.38 0.27 0.12
95 % CI 0.32–0.55 0.10–0.23 0.29–0.34 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a.
ainter-site variance is completely explained (covered) by inter-extraction variance
binter-extraction variance is completely explained (covered) by intra-extraction variance
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The determination of individual markers and the com-
bined assessment of breast cancer molecular subtypes
remained unaffected by variations in tumor cell content or
by the presence of adjacent DCIS. Robust and reprodu-
cible performance at different sites, including independent
molecular pathology labs, where the methodology was in-
troduced for the first time, resulted in highly concordant
molecular subtyping of the tested samples.
Following the discovery of breast cancer molecular
subtypes there have been multiple attempts to translate
the recently acquired knowledge into clinically applic-
able gene-expression-based prognostic signatures and
molecular classification tools [31]. This unprecedented
explosion of diagnostic assays urged the Evaluation of
Genomic Applications in Practice and Prevention
(EGAPP) working group to articulate recommendations
for the experimental development of molecular tests and
the evaluation of supporting clinical utility data [24]. A
major contribution has been the concept that clinical
utility is verified not only upon convincing associations
to clinical outcomes and treatments (clinical validity)
but also through the demonstration of the test’s capacity
to generate specific, sensitive and reproducible data
under standard laboratory conditions (analytical validity)
which is what we demonstrated herein for the Mamma-
Typer IVD test.
Molecular tests currently marketed in breast cancer
diagnostics are required to present published evidence of
adequate analytical performance based on comprehen-
sive technical studies [8, 32]. However, in practice, every-
day prognostic stratification of cancer patients in breast
oncology is based mainly on IHC, sparing proliferation
gene signatures and molecular classifiers for a limited
number of diagnostically challenging and equivocal cases
[33]. Consequently, recent refinements in the criteria for
analytical validity may not necessarily change the land-
scape for the large majority of routinely performed as-
sessments of breast cancer biomarkers for prognosis and
prediction. Of note, the identification of the target group
of costly molecular tests still depends on less reprodu-
cible methods, such as IHC. Thus, reliable and accurate
stratification of breast cancer patients in a practical and
cost-effective way remains an important aim not only for
molecular subtyping, but also for guiding the use of add-
itional molecular assays which often involve shipment of
tissues to distant, central laboratories.
In this study we have presented data on the Mamma-
Typer RT-qPCR assay analytical performance according
to predefined objectives and detailed planning of the val-
idation process. The various analytical surveys, including
those targeting the efficiency of the RNXtract RNA ex-
traction method, were designed so as to satisfy
Table 6 Concordance of dichotomized test results between
sites by qPCR system and between different qPCR platforms.
The calculation of concordance between the two platforms is
based on data from study 2
ERBB2 ESR1 PGR MKI67
Versant kPCR AD 98.1 % 94.7 % 96.3 % 95.1 %
LightCycler 480 II 100.0 % 100.0 % 98.4 % 94.3 %
Between platforms 100.00 % 96.9 % 97.2 % 98.6 %
Fig. 4 Correlation between single measurements and mean values over all measurements of 8 samples on 4 different LightCycler instruments
(total of 24 measurements per sample)
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guidelines issued by expert regulatory bodies such as the
CLSI and MIQE to the highest feasible level. The com-
bined extraction-amplification workflow was tested
across a range of tumor samples that are similar to those
routinely encountered in a clinical laboratory setting in-
cluding both resection specimens and core needle biop-
sies. MammaTyper performed in a consistent and
reproducible manner across that range in line with pub-
lished characteristics of other RT-qPCR-based tests [32].
In addition, the assay was particularly stable not only
within but also outside the specified RNA input limits as
evidenced by concordant calls even upon failure of in-
ternal sample validity controls. Furthermore, consistent
results were obtained: after reduction of input material
to the half of the specified amount; by using alternative
extraction methodologies or by deviating from standard
conditions, lending additional support to the assay’s ana-
lytical robustness.
The precision studies were designed so as to differenti-
ate between assay-specific variations and variation aris-
ing from regular tissue biological heterogeneity across
multiple testing sites and 2 different qPCR platforms.
The results of these studies illustrate that the Mamma-
Typer assay is precise upon repetition over short or lon-
ger intervals of time. The various analytical parameters
yielded only minor discrepancies in the test results.
The highest variance accounting for all measurements
was 0.66 and 0.20 Cq values standard deviation for the
Versant and the Roche cyclers, respectively. The vari-
ance is not identical between experiments conducted on
the two different instruments and this affects all sources
of analytical variation including tumor heterogeneity.
This may indicate that the two platforms differ notice-
ably in terms of the generated analytical noise.
The molecular subtypes of breast cancer can be effect-
ively approximated by surrogate definitions based on the
expression status of only four markers. The extent to
which this approach may be successful, directly relates
to the performance of the methods employed at various
levels of tumor classification and risk stratification.
Herein we have demonstrated that the MammaTyper
test can be reliably performed in a decentralized manner,
yielding highly concordant results under different oper-
ating conditions. The level of accuracy obtained for sin-
gle biomarker status is comparable to the best relevant
numbers reported for HER2, ER and PR across various
IHC studies [34–36]. Particularly for MKI67 the level of re-
producibility achieved herein by RT-qPCR is highly en-
couraging. Reliable and reproducible determination of
tumor proliferation is at the moment difficult to achieve
with IHC given the high discordance rates and difficulties
in achieving guideline-driven improvements for Ki-67 [15].
The adherence to international guidelines, when avail-
able and the explicit validation of laboratory procedures
are the cornerstones of establishing reliable and repro-
ducible diagnostic assay performance. A recent study on
the validation of predictive laboratory-developed IHC as-
says showed that almost half of the participants did not
assess between-run precision and only less than half per-
formed validations according to written protocols [37].
In a similar survey involving HER2, one in four re-
sponders failed to achieve the 95 % concordance rate, a
target set by ASCO/CAP guidelines for positive and
negative cases when comparing results between IHC and
FISH with another IHC laboratory test for HER2 [38].
This alarming failure rate appears to be resistant to im-
provement according to a recent update of this study
[39]. For ER on the other hand, low range expression or
slightly different assay methods yielded different results,
even between experienced observers or certified central
laboratories [34, 40].
The higher reproducibility of RT-qPCR-based deter-
mination of the four breast cancer biomarkers which
our results indicate should be interpreted while keeping
in mind that this is a well designed analytical perform-
ance study which allows adequate control on devices
and reagents and involves sites with more than average
experience in molecular technologies. Therefore, regular
rounds of quality control testing could be of assistance
in achieving and maintaining high assay performance in
local laboratories with variable background in molecular
diagnostic applications. One of the major arguments
against the potential use of RT-qPCR as an alternative to
breast cancer biomarker detection by IHC has been the
risk of false-negatives resulting from dilution of tumor
cell RNA by other sources of RNA or the risk of false
positives due to contamination by DCIS. Herein we
demonstrate that the assessment of ERBB2, ESR1, PGR,
and MKI67 by MammaTyper in primary tumors remains
unaffected by fluctuations in the TCC of FFPE speci-
mens or by the presence of DCIS. Previous work showed
that macrodissection does not alter the prognostic sig-
nificance of ERBB2 and ESR1 mRNA [41] and that high
concordance exists between paired invasive and in situ
lesions when HER2 was assessed by IHC and FISH [42].
Our findings coupled with those of previous investiga-
tors may have direct implications on the handling of
specimens for molecular diagnostics indicating that
time-consuming performance of macrodissection could
be spared at least for some markers.
The data presented herein for the RT-qPCR assay were
obtained by processing of routine FFPE material with the
RNXtract kit. The quality of the results therefore supports
the use of the RNXtract paramagnetic bead assay as a
highly efficient and specific method for RNA extraction
intended for molecular diagnostic applications. In the pre-
analytical factor study the RNXtract performed comparably
to two other established RNA isolation methodologies.
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Furthermore, the high level of preferential RNA isolation
achieved from a single 10 μm-thick section combined with
the specificity of the MammaTyper assay make the use of
DNA digestion unnecessary. This is of importance, as the
effect of DNA digestion on gene expression signatures and
their clinical interpretation has not been explored even for
molecular assays already in routine use.
Conclusions
During the past decades the ASCO/CAP guidelines have
contributed substantially towards raising the level of
standardization of IHC for HER2, ER and PR. Still, marker
discordance rates between local and central testing often
reported in the frame of modern, large clinical trials reveal
the persistence of technical and interpretational limitations.
Particularly for Ki-67, suboptimal analytical performance
renders questionable the use of this marker for the selec-
tion of patients that are candidates for chemotherapy. From
a technical perspective applying RT-qPCR for resolving the
status of ERBB2, ESR1, PGR, and MKI67 represents an effi-
cient and reproducible alternative for decentralized routine
assessment of breast cancer molecular subtypes. Herein we
have provided evidence that the objective quantification of
ERBB2, ESR1, PGR and MKI67 mRNA expression by using
optimally standardized RT-qPCR assays is feasible, sensitive,
specific and analytically precise.
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